Genzyme's orphan-drug unit will have autonomy after buyout

03/2/2011 | Forbes

Genzyme's business for rare-disease drugs will continue to operate independently, with "a large extent of autonomy," once Sanofi-Aventis completes its $20.1 billion takeover of the biotech company, said Hanspeter Spek, Sanofi's president of global operations. However, Sanofi will seek cost-saving measures in overlapping operations, he said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC